AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 366721 — intervention group
Group type: EXPERIMENTAL
Intervention: Unusual trial design (double-blind cross-over)
Number of subjects: 0
Study 31870702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose administration
Number of subjects: 130
Study 31870702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 31185991 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological maltreatment (experienced by 766 participants, 76.6%)
Number of subjects: 1000
Study 31185991 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress
Number of subjects: 1000
Study 28298393 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐wk very‐low‐calorie diet (VLCD; 500 kcal/d)
Number of subjects: 61
Study 28298393 — intervention group
Group type: COMPARATOR
Intervention: 12‐wk low‐calorie diet (1250 kcal/d)
Number of subjects: 61
Study 26092673 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular cooling using femoral devices (Icy catheter, Coolgard, Zoll)
Number of subjects: 400
Study 26092673 — intervention group
Group type: COMPARATOR
Intervention: Basic external cooling using fans, a homemade tent, and ice packs
Number of subjects: 400
Study 23050490 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CM
Number of subjects: 45
Study 23050490 — intervention group
Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 45
Study 21061103 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD biofeedback (visual feedback of flow velocities in the middle cerebral arteries)
Number of subjects: 22
Study 21061103 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD biofeedback (increase signal group)
Number of subjects: 22
Study 21061103 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD biofeedback (decrease signal group)
Number of subjects: 22
Study 21061103 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD biofeedback
Number of subjects: 22
Study 19562559 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone (Propess) application
Number of subjects: 141
Study 17343275 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pallidotomy
Number of subjects: 61
Study 17343275 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the subthalamic nucleus
Number of subjects: 61
Study 17343275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 61
Study 17343275 — intervention group
Group type: COMPARATOR
Intervention: Other interventions
Number of subjects: 61
Study 16366740 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal supplement containing 600 mg black tea extract (60% polyphenols, 20% caffeine) and 442 mg guarana extract (36% caffeine)
Number of subjects: 16
Study 16366740 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 16
Study 11297904 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg CQ
Number of subjects: 36
Study 11297904 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg CQ
Number of subjects: 36
Study 9623442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile assessment of the train‐of‐four (TOF) count and TOF ratio by nursing staff
Number of subjects: 30
Study 9623442 — intervention group
Group type: COMPARATOR
Intervention: TOF-Watch (acceleromyographic monitor)
Number of subjects: 30
Study 7892366 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic orientation tasks
Number of subjects: 0
Study 7892366 — intervention group
Group type: COMPARATOR
Intervention: Explicit memory tests
Number of subjects: 0
Study 7892366 — intervention group
Group type: COMPARATOR
Intervention: Implicit memory tests
Number of subjects: 0
Study 3283227 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol, 20 mg/day
Number of subjects: 17
Study 3283227 — intervention group
Group type: COMPARATOR
Intervention: Verapamil, 240‐480 mg/day
Number of subjects: 17
Study 29471185 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Training Technique (ATT)
Number of subjects: 101
Study 29471185 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 101
Study 29471185 — intervention group
Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 101
Study 27719677 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers' knowledge and practice regarding pre-eclampsia identification and treatment
Number of subjects: 34
Study 27719677 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and equipment availability for community health workers
Number of subjects: 34
Study 27719677 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular training and retraining for community health workers
Number of subjects: 34
Study 24742190 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study 24742190 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (no-contact control group)
Number of subjects: 0
Study 23277147 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary nitrate secretion after stress activity
Number of subjects: 22
Study 23277147 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary nitrite levels after stress activity
Number of subjects: 22
Study 23277147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric nitrate administration in BPSDL rats
Number of subjects: 22
Study 23277147 — intervention group
Group type: COMPARATOR
Intervention: Gastric ulcer index (UI) in BPSDL rats
Number of subjects: 22
Study 20132103 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 1590
Study 20132103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg
Number of subjects: 1590
Study 20132103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1590
Study 17522618 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-methyltetrahydrofolate (1 mg)
Number of subjects: 60
Study 17522618 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (1 mg)
Number of subjects: 60
Study 17522618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15860689 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise, 5 times per week for 60 minutes at moderate intensity (approximately 60% peak oxygen uptake)
Number of subjects: 24
Study 14668077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride
Number of subjects: 30
Study 14668077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14668077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (subgroup analysis by genotype)
Number of subjects: 30
Study 11123867 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 11123867 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 0
Study 11123867 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary systemic chemotherapy
Number of subjects: 0
Study 8833458 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% cinnamic aldehyde in ethanol (patch test)
Number of subjects: 18
Study 8833458 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% cinnamic aldehyde in ethanol (use test)
Number of subjects: 18
Study 8833458 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch test sensitivity
Number of subjects: 18
Study 1424058 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilens contact lens
Number of subjects: 42
Study 1424058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐Tech contact lens
Number of subjects: 42
Study 6740101 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trivalent poliovirus vaccine (OPV)
Number of subjects: 439
Study 6740101 — intervention group
Group type: COMPARATOR
Intervention: Injectable trivalent poliovirus vaccine (IPV)
Number of subjects: 439
Study 31292644 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 435
Study 31292644 — intervention group
Group type: EXPERIMENTAL
Intervention: Central obesity
Number of subjects: 435
Study 31292644 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL
Number of subjects: 435
Study 31292644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertriglyceridaemia
Number of subjects: 435
Study 31527167 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 0
Study 31527167 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 0
Study 28255750 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic self-monitoring app
Number of subjects: 116
Study 28255750 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic app plus goal setting
Number of subjects: 116
Study 28255750 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic app plus points-based feedback
Number of subjects: 116
Study 28255750 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic app plus both modules (goal setting and points-based feedback)
Number of subjects: 116
Study 25294560 — intervention group
Group type: EXPERIMENTAL
Intervention: direct MRI (dMRI) arthrography
Number of subjects: 10
Study 25294560 — intervention group
Group type: EXPERIMENTAL
Intervention: indirect MRI (iMRI) arthrography
Number of subjects: 10
Study 23968880 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient Families intervention (social relationship curriculum for students, parent education handbooks, and events)
Number of subjects: 2354
Study 23968880 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient Families intervention
Number of subjects: 2354
Study 23968880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2354
Study 20957379 — intervention group
Group type: EXPERIMENTAL
Intervention: Foetal fibronectin testing (fFN)
Number of subjects: 88
Study 20957379 — intervention group
Group type: COMPARATOR
Intervention: Preterm labour management without fFN
Number of subjects: 88
Study 19844113 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.066 mg/kg/day
Number of subjects: 25
Study 19844113 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (14 age-matched preterm SGA)
Number of subjects: 25
Study 16150843 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal diastolic function indexes in diabetic subjects
Number of subjects: 21
Study 16150843 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal diastolic function indexes in nondiabetic controls
Number of subjects: 21
Study 12873921 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (gradually decreasing concentration from 8% to clinical awakening)
Number of subjects: 33
Study 12873921 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (steady-state at 1 and 2 MAC)
Number of subjects: 33
Study 10695417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg TID for 2 weeks)
Number of subjects: 51
Study 10695417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8942586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) at a dose of 15 micrograms/kg
Number of subjects: 19
Study 8942586 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge/IV fentanyl
Number of subjects: 19
Study 1821296 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 417
Study 1821296 — intervention group
Group type: COMPARATOR
Intervention: No nicotine gum (control)
Number of subjects: 417
Study 6798584 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 33
Study 6798584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 6377878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine plus a blinded nasogastric tube
Number of subjects: 45
Study 6377878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine plus nasogastric suction
Number of subjects: 45
Study 6377878 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric suction plus cimetidine placebo
Number of subjects: 45
Study 6377878 — intervention group
Group type: COMPARATOR
Intervention: Blinded nasogastric tube plus cimetidine placebo
Number of subjects: 45
Study 30185428 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy‐Health Care (6-month home‐ and community‐based treatment)
Number of subjects: 167
Study 30185428 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (weekly family supportive counseling for 6 months)
Number of subjects: 167
Study 25831410 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobble board rehabilitation (REH) for 4 weeks, 3 sessions per week of 5 repetitions
Number of subjects: 34
Study 25831410 — intervention group
Group type: COMPARATOR
Intervention: No intervention (CON)
Number of subjects: 34
Study 25831410 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobble board rehabilitation (REH)
Number of subjects: 34
Study 24829969 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform switching abutments
Number of subjects: 68
Study 24829969 — intervention group
Group type: COMPARATOR
Intervention: Platform matching abutments
Number of subjects: 68
Study 23117724 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty and stenting (PTAS)
Number of subjects: 70
Study 23117724 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (aspirin 100mg plus clopidogrel 75 mg/d)
Number of subjects: 70
Study 20975461 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/paravertebral anesthesia‐analgesia
Number of subjects: 32
Study 20975461 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/opioid
Number of subjects: 32
Study 18370571 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (3.4 g/d)
Number of subjects: 36
Study 18370571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15728439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (120 mg, one capsule/day for 6 weeks)
Number of subjects: 87
Study 15728439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching capsule for 6 weeks)
Number of subjects: 87
Study 12971422 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (2.3 g per day)
Number of subjects: 41
Study 12971422 — intervention group
Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 41
Study 12971422 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols
Number of subjects: 41
Study 10550273 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg twice daily for a mean of 26 days (range 17-35 days)
Number of subjects: 32
Study 10550273 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 32
Study 8941586 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis with SPAN membranes
Number of subjects: 0
Study 8941586 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis with PS membranes
Number of subjects: 0
Study 8941586 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 0
Study 8941586 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis (general)
Number of subjects: 0
Study 1794921 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of new medication
Number of subjects: 60
Study 1794921 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of new medication
Number of subjects: 60
Study 1794921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1794921 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated liver enzymes
Number of subjects: 60
Study 1794921 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal liver enzymes
Number of subjects: 60
Study 6135635 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion at a constant rate of 250 μg/h from 22.00 h until 07.00 h
Number of subjects: 7
Study 6135635 — intervention group
Group type: COMPARATOR
Intervention: Control test (saline infusion)
Number of subjects: 7
Study 31580005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest dose resulting in 24-hour lasting purpura
Number of subjects: 56
Study 31580005 — intervention group
Group type: COMPARATOR
Intervention: Lowest dose resulting in vessel disappearance observed by dermoscope
Number of subjects: 56
Study 29658440 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency TENS (4 Hz)
Number of subjects: 28
Study 29658440 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency TENS (100 Hz)
Number of subjects: 28
Study 29658440 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 28
Study 26878710 — intervention group
Group type: EXPERIMENTAL
Intervention: VD3-rCM
Number of subjects: 0
Study 26878710 — intervention group
Group type: EXPERIMENTAL
Intervention: VD3-PS80
Number of subjects: 0
Study 26878710 — intervention group
Group type: COMPARATOR
Intervention: VD3-free placebo yogurt
Number of subjects: 0
Study 25249415 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g cinnamon twice a day for 12 weeks
Number of subjects: 21
Study 25249415 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 21
Study 22251435 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab induction therapy (5 or 10 mg/kg every 8 weeks beginning at week 14)
Number of subjects: 212
Study 22251435 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment with CRP normalization (decrease from 0.5 mg/dL at baseline to < 0.5 mg/dL at week 14)
Number of subjects: 212
Study 22251435 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment at week 14 with low CRP levels
Number of subjects: 212
Study 21134045 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (24 U)
Number of subjects: 381
Study 21134045 — intervention group
Group type: COMPARATOR
Intervention: onabotulinumtoxinA
Number of subjects: 381
Study 17617517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 3
Study 17617517 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy
Number of subjects: 3
Study 15652906 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% trichloroacetic acid (TCA) instillation into uterine cavity
Number of subjects: 90
Study 15652906 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone analogue (1 month before procedure)
Number of subjects: 90
Study 15652906 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% TCA instillation
Number of subjects: 90
Study 15652906 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone analogue
Number of subjects: 90
Study 14563391 — intervention group
Group type: EXPERIMENTAL
Intervention: Tin(II) chloride at concentrations of <0.5, 161, 264, and 529 mg/kg in 250 ml tomato juice
Number of subjects: 44
Study 14563391 — intervention group
Group type: COMPARATOR
Intervention: Tin migrated from packaging at concentrations of <0.5, 201, and 267 mg/kg in 250 ml tomato soup
Number of subjects: 44
Study 10397651 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated TPS implants
Number of subjects: 65
Study 10397651 — intervention group
Group type: COMPARATOR
Intervention: TPS cylinder implants
Number of subjects: 65
Study 7740821 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention using a sun protection curriculum
Number of subjects: 508
Study 7740821 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer education)
Number of subjects: 508
Study 2202538 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ultrasound examination
Number of subjects: 0
Study 2202538 — intervention group
Group type: COMPARATOR
Intervention: Selective ultrasound examination (control)
Number of subjects: 0
Study 7270871 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 0
Study 30785357 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-RIT (Priorix, GSK)
Number of subjects: 4011
Study 30785357 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-RIT with DTaP-IPV and VV
Number of subjects: 4011
Study 30785357 — intervention group
Group type: COMPARATOR
Intervention: MMR-RIT and MMR II
Number of subjects: 4011
Study 28704492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment MMP9 levels in CSF (median [interquartile range], 254 [115‐389] ng/mL in good outcome group)
Number of subjects: 40
Study 28704492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment MMP9 levels in CSF (median [interquartile range], 192 [60‐383] ng/mL in poor outcome group)
Number of subjects: 40
Study 28704492 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF glucose levels correlation with MMP9 levels
Number of subjects: 40
Study 28704492 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission Glasgow coma scale score correlation with MMP9 levels
Number of subjects: 40
Study 28704492 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP1 levels in CSF (1239 [889‐1511] ng/mL in good outcome group)
Number of subjects: 40
Study 28704492 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP1 levels in CSF (1522 [934‐1949] ng/mL in poor outcome group)
Number of subjects: 40
Study 28704492 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP9/TIMP1 ratio (0.191 [0.107‐0.250] in good outcome group)
Number of subjects: 40
Study 28704492 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP9/TIMP1 ratio (0.163 [0.067‐0.34] in poor outcome group)
Number of subjects: 40
Study 24711613 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS), 1-Hz, right prefrontal, for 4 weeks.
Number of subjects: 50
Study 24711613 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER, for 4 weeks.
Number of subjects: 50
Study 24711613 — intervention group
Group type: COMPARATOR
Intervention: Comparison of predictive efficacy between rTMS and venlafaxine ER.
Number of subjects: 50
Study 23584289 — intervention group
Group type: EXPERIMENTAL
Intervention: DE plus placebo (DEP)
Number of subjects: 13
Study 23584289 — intervention group
Group type: EXPERIMENTAL
Intervention: DE with N-acetylcysteine supplementation (DEN)
Number of subjects: 13
Study 23584289 — intervention group
Group type: COMPARATOR
Intervention: Filtered air plus placebo (FAP)
Number of subjects: 13
Study 21721593 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)V/DNG
Number of subjects: 58
Study 21721593 — intervention group
Group type: COMPARATOR
Intervention: EE/LNG
Number of subjects: 58
Study 19170687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19